Soft‐Drug‐Inspired MnSTF Nano‐Adjuvant for Safe and Synergistic cGAS–STING Activation in Tumor Immunotherapy
Advanced Science · 2026-02 · 13 (9)
DOI: 10.1002/advs.202515432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 16.12.2025. Verfasst von Guangfei Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, Medical School and School of Life Science, Nanjing University, Nanjing, 210093, P. R. China. Hauptthemen laut MEDLINE: Immunotherapy, Nucleotidyltransferases, Membrane Proteins, Adjuvants, Immunologic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key Research and Development Program of China, Natural Science Foundation of Jiangsu Province, Logistics research projects.
Abstract (Originalsprache)
The activation of the stimulator of interferon genes (STING) pathway is a cutting‐edge strategy in tumor immunotherapy and has shown transformative potential in preclinical studies by inducing a type I interferon cascade and remodeling the tumor immune microenvironment. However, current STING agonists are limited by a narrow therapeutic window and substantial systemic toxicity, which significantly impedes their translational potential. To overcome these challenges, a novel self‐assembling nanoadjuvant, MnSTF, grounded in the soft‐drug design paradigm is designed. MnSTF is assembled through multidentate coordination between manganese ions (Mn 2+ ), which exhibit moderate STING‐activating activity, and the ENPP1 inhibitor STF‐1623, thereby achieving synergistic activation of the cGAS–STING signaling axis. In contrast to conventional small‐molecule STING agonists, MnSTF elicits no systemic inflammatory response at either therapeutic or supratherapeutic doses, demonstrating outstanding safety and biocompatibility. Furthermore, MnSTF profoundly reprograms the tumor immune microenvironment and, when coadministered with radiotherapy, mRNA vaccines, or protein antigens, induces robust antigen‐specific T cell responses and marked antitumor efficacy. Accordingly, by combining soft‐drug design with a dual‐targeted immunomodulatory mechanism, MnSTF effectively reconciles the efficacy–safety trade‐off of STING agonists in preclinical settings and expands the potential for precise immunoregulation via the STING pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Pharmaceutical Biotechnology, Medical School and School of Life Science, Nanjing University, Nanjing, 210093, P. R. China.
- Jiangsu Key Laboratory for Nano Technology, Nanjing University, Nanjing, 210093, P. R. China.
- Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210093, P. R. China.
ORCID-Profile: Yiqiao Hu
Förderung
- the National Key Research and Development Program of China
- Natural Science Foundation of Jiangsu Province
- Logistics research projects
- National Natural Science Foundation of China
Zitieren
APA
Sun, G., Pan, J., Li, R., Li, R., Liu, Z., Wu, J., Lin, T., Hu, Y., & Yuan, A. (2026). Soft‐Drug‐Inspired MnSTF Nano‐Adjuvant for Safe and Synergistic cGAS–STING Activation in Tumor Immunotherapy. Advanced Science, 13(9). https://doi.org/10.1002/advs.202515432
Vancouver
Sun G, Pan J, Li R, Li R, Liu Z, Wu J, et al. Soft‐Drug‐Inspired MnSTF Nano‐Adjuvant for Safe and Synergistic cGAS–STING Activation in Tumor Immunotherapy. Advanced Science. 2026;13(9). doi:10.1002/advs.202515432
BibTeX
@article{Sun2026,
author = {Sun, Guangfei and Pan, Jiancheng and Li, Rui and Li, Ruoxi and Liu, Ziyan and Wu, Jinhui and Lin, Tingsheng and Hu, Yiqiao and Yuan, Ahu},
title = {Soft‐Drug‐Inspired MnSTF Nano‐Adjuvant for Safe and Synergistic cGAS–STING Activation in Tumor Immunotherapy},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {9},
doi = {10.1002/advs.202515432}
}
EUVIMED